Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of drug interactions in elderly patients with multimorbidity in primary care

  • Review Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Drug interactions (DIs) are a significant cause of medication-related problems. The aging population, high chronic diseases prevalence and polypharmacy are closely associated factors. Aim of the review To study the prevalence, types and associated factors of DIs in multimorbidity patients of over 65 years of age in primary care. Methods Relevant studies on DI prevalence in this population were reviewed in PubMed, Cochrane Library and EMBASE (January 2000–December 2015). Independent variables (duration, target population, age, sex, mean of drugs and diseases, geographical localization, DI databases used and study designs) and dependent variables (prevalence, number of DIs per 100 patients and per patient, number of clinically-relevant DIs per 100 patients, most common DI and associated factors) were classified for each article. Results The search generated 749 articles and 46 duplicates were discarded. After reviewing, 10 articles were included. Seven studies were observational and 3 were quasi-experimental. Seven out of 10 used interaction databases. Only 2 studies described both actual and potential DIs. The prevalence of multimorbidity patients with DI ranged from 25.1 to 100% and the number of DIs per 100 patients was from 30 to 388.3. All the lower values correspond to the study conducted at the nursing home. This could be due to special care offered in these centres, where the medication is more controlled. The most frequent DIs were reported in five articles. However, these results could not be correlated since they were ranked using different methodologies. ACEIs, diuretics and NSAID were the most common therapeutic groups. Finally, 5 studies identified factors associated with the presence of potential DIs. The number of drugs and age were the most significant factors. Conclusions There is little evidence of prevalence of actual and potential DIs in elderly patients with multimorbidity in outpatient settings, showing widely heterogeneous results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lenssen R, Heidenreich A, Schulz JB, Trautwein C, Fitzner C, Jaehde U, et al. Analysis of drug-related problems in three departments of a German University hospital. Int J Clin Pharm. 2016;38:119–26.

    Article  PubMed  Google Scholar 

  2. Sharifi H, Hasanloei MA, Mahmoudi J. Polypharmacy-induced drug-drug interactions; threats to patient safety. Drug Res (Stuttg). 2014;64:633–7.

    Article  CAS  PubMed  Google Scholar 

  3. Parker MG, Thorslund M. Health trends in the elderly population: gettingbetter and getting worse. Gerontologist. 2007;47:150–8.

    Article  PubMed  Google Scholar 

  4. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716–24.

    Article  CAS  PubMed  Google Scholar 

  5. Opondo D, Eslami S, Visscher S, de Rooij SE, Verheij R, Korevaar JC, et al. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PLoS ONE. 2012;7(8):e43617.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Panagioti M, Stokes J, Esmail A, Coventry P, Cheraghi-Sohi S, Alam R, Bower P. Multimorbidity and patient safety incidents in primary care: a systematic review and meta-analysis. PLoS ONE. 2015;10(8):e0135947.

    Article  PubMed  PubMed Central  Google Scholar 

  7. World Health Organisation. Definition of an older or elderly person. WHO, Geneva, Switzerland. 2010. http://www.who.int/healthinfo/survey/ageingdefnolder/en/index.html. Accessed 15 Aug 2016.

  8. Orimo H, Ito H, Suzuki T, Araki A, Hosoi T, Sawabe M. Reviewing the definition of “elderly”. Geriatr Gerontol Int. 2006;6:149–58.

    Article  Google Scholar 

  9. Nabovati E, Vakili-Arki H, Taherzadeh Z, Hasibian MR, Abu-Hanna A, Eslami S. Drug-drug interactions in inpatient and outpatient settings in Iran: a systematic review of the literature. Daru. 2014;25(22):52.

    Article  Google Scholar 

  10. Doubova-Dubova SV, Reyes-Morales H, Torres-Arreola LP, Suárez-Ortega M. Potential drug drug and drug disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res. 2007;19(7):147.

    Article  Google Scholar 

  11. Liao HL, Chen JT, Ma TC, Chang YS. Analysis of drug-drug interactions (DDIs) in nursing home in Central Taiwan. Arch Gerontol Geriatr. 2008;47:99–107.

    Article  PubMed  Google Scholar 

  12. Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drugdrug interactions in Regione EmiliaRomagna, Italy. J Clin Pharm Ther. 2008;33:14151.

    Article  Google Scholar 

  13. Tulner LR, Frankfort SV, Gijsen GJ, van Campen JP, Koks CH, Beijnen JH. Drug drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25:3435.

    Article  Google Scholar 

  14. Galindo-Ocaña J, Gil-Navarro MV, García-Morillo JS, Bernabeu-Wittel M, Ollero-Baturone M, Ortiz-Camuñez MA. Drug drug interactions in multicentre polypathological polymedicated patients. Rev Clin Esp. 2010;210:2708.

    Google Scholar 

  15. Fiss T, Dreier A, Meinke C, van den Berg N, Ritter CA, Hoffmann W. Detection of drug related problems in an interdisciplinary health care model for rural areas in Germany. Pharm World Sci. 2010;32:566–74.

    Article  PubMed  Google Scholar 

  16. Hoffmann W, van den Berg N, Thyrian JR, Fiss T. Frequency and determinants of potential drug drug interactions in an elderly population receiving regular home visits by Gps results of the home medication review in the AgnESstudies. Pharmacoepidemiol Drug Saf. 2011;20:13118.

    Google Scholar 

  17. Marusic S, BacicVrca V, Obreli Neto PR, Franic M, Erdeljic V, GojoTomic N. Actual drugdrug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69:171724.

    Article  Google Scholar 

  18. Fiß T, MeinkeFranze C, van den Berg N. Hoffmann W Effects of a three party healthcare network on the incidence levels of drug related problems. Int J Clin Pharm. 2013;35:76371.

    Article  Google Scholar 

  19. Bazargan M, Yazdanshenas H, Han S, Orum G. Inappropriate medication use among underserved elderly African Americans. J Aging Health. 2016;28:118–38.

    Article  PubMed  Google Scholar 

  20. Malone DC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, Van Bergen RC, Duncan-Edgar BS, Solomon SL, Lipton RB. Identification of serious drug–drug interactions: results of the partnership to prevent drug–drug interactions. J Am Pharm Assoc. 2004;44:142–51.

    Article  Google Scholar 

  21. Samsa GP, Hanlon JT, Schmader KE. A summated score for theMedication Appropriateness Index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol. 1994;47:891–6.

    Article  CAS  PubMed  Google Scholar 

  22. Charlson ME, Pompei P, Ales KA, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies. J Chron Dis. 1987;40:373–83.

    Article  CAS  PubMed  Google Scholar 

  23. Maio V, Yuen EJ, Novielli K, Smith KD, Louis DZ. Potentially inappropriate medication prescribing for elderly outpatients in Emilia Romagna, Italy: a population-based cohort study. Drugs Aging. 2006;23:915–24.

    Article  PubMed  Google Scholar 

  24. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33:783–95.

    Article  CAS  PubMed  Google Scholar 

  25. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370:185–91.

    Article  CAS  PubMed  Google Scholar 

  26. Dechamont S, Maphanta S, Butthum B, Kongkew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489–97.

    Article  Google Scholar 

  27. Björkman IK, Fastbom J, Schmidt IK, Bernsten CB, the Pharmaceutical Care of the Elderly in Europe Research (PEER) Group. Drug–drug interactions in the elderly. Ann Pharmacother. 2002;36:1675–81.

    Article  PubMed  Google Scholar 

  28. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc. 2003;2004(44):136–41.

    Google Scholar 

  29. Rodríguez-Terol A, Caraballo MO, Palma D, Santos-Ramos B, Molina T, Desongles T, et al. Quality of interaction database management systems. Farm Hosp. 2009;33:134–46.

    Article  PubMed  Google Scholar 

  30. Zhang Y, Baicker K, Newhouse JP. Geographic variation in the quality of prescribing. N Engl J Med. 2010;363:1985–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother. 2004;2:274–302.

    Article  CAS  PubMed  Google Scholar 

  32. Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12:646–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Uijtendaal EV, Zwart-van Rijkom JE, van Solinge WW, Egberts TC. Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium; oncentration increasing drugs. Eur J Clin Pharmacol. 2011;67:933–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Zwart-van Rijkom JE, Uijtendaal EV, ten Berg MJ, van Solinge WW, Egberts AC. Frequency and nature of drug–drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2009;68:187–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Cruciol-Souza JM, Thomson JC. Prevalence of potential drugdrug interactions and its associated factors in a Brazilian teaching hospital. Pharm Pharm Sci. 2006;9:427–33.

    CAS  Google Scholar 

  36. Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther. 2005;30:13–20.

    Article  CAS  PubMed  Google Scholar 

  37. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly. Drug Saf. 2007;30:911–8.

    Article  PubMed  Google Scholar 

  38. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value innthe assessment of drug-related problems. Br J Clin Pharmacol. 2007;63:187–95.

    Article  PubMed  Google Scholar 

  39. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11:83–94.

    Article  CAS  PubMed  Google Scholar 

  40. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: “There’s got to be a happy medium”. JAMA. 2010;304:1592–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. National Institute for Health and Care Excellence (NICE). Multimorbidity: clinical assessment and management. London, United Kingdom, 2016. https://www.nice.org.uk/guidance/ng56. Accessed 15 Dec 2016.

Download references

Funding

None.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Pharmacy Service, University Hospital Valme, Avenida de Bellavista s/n, 41014, Seville, Spain

    Susana Sánchez-Fidalgo, Maria Isabel Guzmán-Ramos, Mercedes Galván-Banqueri & Bernardo Santos-Ramos

  2. Internal Medicine Service, University Hospital Virgen del Rocio, Seville, Spain

    Máximo Bernabeu-Wittel

Authors
  1. Susana Sánchez-Fidalgo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Isabel Guzmán-Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mercedes Galván-Banqueri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Máximo Bernabeu-Wittel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bernardo Santos-Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susana Sánchez-Fidalgo.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sánchez-Fidalgo, S., Guzmán-Ramos, M.I., Galván-Banqueri, M. et al. Prevalence of drug interactions in elderly patients with multimorbidity in primary care. Int J Clin Pharm 39, 343–353 (2017). https://doi.org/10.1007/s11096-017-0439-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-017-0439-1

Keywords

Search

Navigation